Published in Am J Psychiatry on March 01, 2002
Fish Oil for the Treatment of Depression in Patients With Multiple Sclerosis | NCT00122954
A Prophylactic Trial of Omega-3 Polyunsaturated Fatty Acids in Bipolar Disorder | NCT04210804
Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis. Mol Psychiatry (2011) 2.32
Yoga as a complementary treatment of depression: effects of traits and moods on treatment outcome. Evid Based Complement Alternat Med (2007) 2.22
Evidence-based kernels: fundamental units of behavioral influence. Clin Child Fam Psychol Rev (2008) 2.01
Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J Clin Psychiatry (2011) 1.81
Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease: a randomized controlled trial. JAMA (2009) 1.79
Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid? Lipids Health Dis (2007) 1.51
Role of nutraceuticals in human health. J Food Sci Technol (2011) 1.49
Nutrition and depression: implications for improving mental health among childbearing-aged women. Biol Psychiatry (2005) 1.46
Long chain omega-3 fatty acids intake, fish consumption and mental disorders in the SUN cohort study. Eur J Nutr (2007) 1.45
Efficacy of omega-3 for vasomotor symptoms treatment: a randomized controlled trial. Menopause (2014) 1.44
Eating ourselves to death (and despair): the contribution of adiposity and inflammation to depression. Prog Neurobiol (2010) 1.38
Marine bioactives as functional food ingredients: potential to reduce the incidence of chronic diseases. Mar Drugs (2011) 1.36
Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials. PLoS One (2014) 1.32
Higher dietary intake of long-chain omega-3 polyunsaturated fatty acids is inversely associated with depressive symptoms in women. Nutrition (2009) 1.11
A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder. J Clin Psychiatry (2009) 1.09
Environmental and pharmacological modulations of cellular plasticity: role in the pathophysiology and treatment of depression. Neurobiol Dis (2012) 1.07
Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder. J Clin Psychopharmacol (2012) 1.05
Omega-3 fatty acids and major depression: a primer for the mental health professional. Lipids Health Dis (2004) 1.03
Mood disorders and complementary and alternative medicine: a literature review. Neuropsychiatr Dis Treat (2013) 0.98
Plasma free polyunsaturated fatty acid levels are associated with symptom severity in acute mania. Bipolar Disord (2007) 0.96
Omega-3 fatty acids for depression in adults. Cochrane Database Syst Rev (2015) 0.96
Oiling the brain: a review of randomized controlled trials of omega-3 fatty acids in psychopathology across the lifespan. Nutrients (2010) 0.96
Fatty acid composition in postmortem brains of people who completed suicide. J Psychiatry Neurosci (2007) 0.95
Daily omega-3 fatty acid intake and depression in Japanese patients with newly diagnosed lung cancer. Br J Cancer (2004) 0.95
Age-related changes of n-3 and n-6 polyunsaturated fatty acids in the anterior cingulate cortex of individuals with major depressive disorder. Prostaglandins Leukot Essent Fatty Acids (2010) 0.94
Acute coronary syndrome patients with depression have low blood cell membrane omega-3 fatty acid levels. Psychosom Med (2008) 0.89
Antioxidants as potential therapeutics for neuropsychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry (2012) 0.89
Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder. Transl Psychiatry (2016) 0.89
The effect of low-dose omega 3 fatty acids on the treatment of mild to moderate depression in the elderly: a double-blind, randomized, placebo-controlled study. Eur Arch Psychiatry Clin Neurosci (2011) 0.86
Omega-3 polyunsaturated fatty acid (PUFA) status in major depressive disorder with comorbid anxiety disorders. J Clin Psychiatry (2013) 0.86
Long-chain n-3 polyunsaturated fatty acids decrease feelings of anger in substance abusers. Psychiatry Res (2007) 0.86
Associations between increases in plasma n-3 polyunsaturated fatty acids following supplementation and decreases in anger and anxiety in substance abusers. Prog Neuropsychopharmacol Biol Psychiatry (2007) 0.84
Omega-3 Polyunsaturated Fatty Acids in Prevention of Mood and Anxiety Disorders. Clin Psychopharmacol Neurosci (2015) 0.84
Inflammation in depression: is adiposity a cause? Dialogues Clin Neurosci (2011) 0.83
Nutrition and depression at the forefront of progress. J Med Life (2012) 0.83
Emerging targets for antidepressant therapies. Curr Opin Chem Biol (2009) 0.82
Acute appearance of fatty acids in human plasma--a comparative study between polar-lipid rich oil from the microalgae Nannochloropsis oculata and krill oil in healthy young males. Lipids Health Dis (2013) 0.82
Effects of n-3 fatty acids on depressive symptoms and dispositional optimism after myocardial infarction. Am J Clin Nutr (2011) 0.81
Omega-3 fatty acids decreased irritability of patients with bipolar disorder in an add-on, open label study. Nutr J (2005) 0.81
Complementary and alternative medicine therapies for perinatal depression. Best Pract Res Clin Obstet Gynaecol (2013) 0.80
Complementary and alternative medicine therapies to promote healthy moods. Pediatr Clin North Am (2007) 0.80
Novel targets for antidepressant therapies. Curr Psychiatry Rep (2008) 0.80
Supplementation with Omega-3 Fatty Acids in Psychiatric Disorders: A Review of Literature Data. J Clin Med (2016) 0.80
N-3 Polyunsaturated Fatty Acids through the Lifespan: Implication for Psychopathology. Int J Neuropsychopharmacol (2016) 0.80
Possible deleterious effects of adjunctive omega-3 fatty acids in post-traumatic stress disorder patients. Neuropsychiatr Dis Treat (2005) 0.79
Update and critique of natural remedies as antidepressant treatments. Obstet Gynecol Clin North Am (2009) 0.79
Glia in the cytokine-mediated onset of depression: fine tuning the immune response. Front Cell Neurosci (2015) 0.79
(N-3) Fatty acids: molecular role and clinical uses in psychiatric disorders. Adv Nutr (2012) 0.79
An Evidence-Based Approach to Augmentation and Combination Strategies for: Treatment-Resistant Depression. Psychiatry (Edgmont) (2006) 0.78
ω-3 Fatty acids for major depressive disorder in adults: an abridged Cochrane review. BMJ Open (2016) 0.78
The Role of Nutrients in Protecting Mitochondrial Function and Neurotransmitter Signaling: Implications for the Treatment of Depression, PTSD, and Suicidal Behaviors. Crit Rev Food Sci Nutr (2016) 0.78
Omega-3 polyunsaturated fatty acid supplementation and white matter changes in major depression. J Psychiatr Res (2016) 0.78
Neuroticism but not omega-3 fatty acid levels correlate with early responsiveness to escitalopram. Ann Clin Psychiatry (2010) 0.78
Maternal omega-3 fatty acid supplementation and risk for perinatal maternal depression. J Matern Fetal Neonatal Med (2010) 0.77
Combined application of eicosapentaenoic acid and docosahexaenoic acid on depression in women: a meta-analysis of double-blind randomized controlled trials. Neuropsychiatr Dis Treat (2015) 0.77
Associations of the Ratios of n-3 to n-6 Dietary Fatty Acids With Longitudinal Changes in Depressive Symptoms Among US Women. Am J Epidemiol (2015) 0.77
Levels of omega-3 fatty acid in serum phospholipids and depression in patients with lung cancer. Br J Cancer (2005) 0.77
Early intervention of intravenous KB220IV--neuroadaptagen amino-acid therapy (NAAT) improves behavioral outcomes in a residential addiction treatment program: a pilot study. J Psychoactive Drugs (2013) 0.76
Comments on Bozzatello et al. Supplementation with Omega-3 Fatty Acids in Psychiatric Disorders: A Review of Literature Data. J. Clin. Med. 2016, 5, 67. J Clin Med (2016) 0.76
Promising avenues of therapeutics for bipolar illness. Dialogues Clin Neurosci (2008) 0.76
Effect of Citalopram in Combination with Omega-3 on Depression in Post-menopausal Women: A Triple Blind Randomized Controlled Trial. J Clin Diagn Res (2016) 0.75
Particle formation and characterization of mackerel reaction oil by gas saturated solution process. J Food Sci Technol (2015) 0.75
The efficacy of fish oil supplements in the treatment of depression: food for thought. Transl Psychiatry (2016) 0.75
Associations between omega fatty acid consumption and depressive symptoms among individuals seeking behavioural weight loss treatment. Obes Sci Pract (2016) 0.75
Universities, governments and industry: can the essential nature of universities survive the drive to commercialize? J Psychiatry Neurosci (2005) 0.75
Polyunsaturated fatty acids moderate the effect of poor sleep on depression risk. Prostaglandins Leukot Essent Fatty Acids (2015) 0.75
Lipid correlates of antidepressant response to omega-3 polyunsaturated fatty acid supplementation: A pilot study. Prostaglandins Leukot Essent Fatty Acids (2017) 0.75
Long-chain omega-3 fatty acids and optimization of cognitive performance. Mil Med (2014) 0.75
Omega-3 Fatty Acids for Depression in Multiple Sclerosis: A Randomized Pilot Study. PLoS One (2016) 0.75
The Relationship between Fatty Acids and Different Depression-Related Brain Regions, and Their Potential Role as Biomarkers of Response to Antidepressants. Nutrients (2017) 0.75
Tackling partial response to depression treatment. Prim Care Companion J Clin Psychiatry (2009) 0.75
N-3 (omega-3) Fatty acids in postpartum depression: implications for prevention and treatment. Depress Res Treat (2010) 0.75
Omega-3 Polyunsaturated Fatty Acids and Oxylipins in Neuroinflammation and Management of Alzheimer Disease. Adv Nutr (2016) 0.75
Insights into the function of n-3 PUFAs in fat-1 transgenic cattle. J Lipid Res (2017) 0.75
Backing into the future: pharmacological approaches to the management of resistant depression. Psychol Med (2017) 0.75
Dopamine D4 receptor (D4DR) exon III polymorphism associated with the human personality trait of Novelty Seeking. Nat Genet (1996) 2.92
Genetic linkage between X-chromosome markers and bipolar affective illness. Nature (1987) 2.44
World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res (2008) 1.84
Subtyping major depressive disorder. Psychother Psychosom (2010) 1.76
Association between tridimensional personality questionnaire (TPQ) traits and three functional polymorphisms: dopamine receptor D4 (DRD4), serotonin transporter promoter region (5-HTTLPR) and catechol O-methyltransferase (COMT). Mol Psychiatry (2000) 1.74
Transcranial magnetic stimulation in mania: a controlled study. Am J Psychiatry (1998) 1.71
Lithium inhibits adrenergic and cholinergic increases in GTP binding in rat cortex. Nature (1988) 1.67
Elevated homocysteine levels in young male patients with schizophrenia. Am J Psychiatry (2002) 1.62
Omega-3 eicosapentaenoic acid in bipolar depression: report of a small open-label study. J Clin Psychiatry (2005) 1.54
Computerized testing of neurocognitive function in euthymic bipolar patients compared to those with mild cognitive impairment and cognitively healthy controls. Psychother Psychosom (2011) 1.46
Omega-3 treatment of childhood depression: a controlled, double-blind pilot study. Am J Psychiatry (2006) 1.43
Absence of prion protein mutation in bipolar manic-depressive patients. Br J Psychiatry (1992) 1.36
Antidepressive-like effects of rapamycin in animal models: Implications for mTOR inhibition as a new target for treatment of affective disorders. Brain Res Bull (2008) 1.26
Trafficked female sex workers awaiting deportation: comparison with brothel workers. Arch Womens Ment Health (2004) 1.20
The mechanism of lithium action: state of the art, ten years later. Prog Neuropsychopharmacol Biol Psychiatry (2001) 1.20
Ritual female genital surgery among Bedouin in Israel. Arch Sex Behav (1995) 1.15
The motivation and mental health of sex workers. J Sex Marital Ther (2002) 1.14
GSK-3 and the neurodevelopmental hypothesis of schizophrenia. Eur Neuropsychopharmacol (2002) 1.13
Glycogen synthase kinase-3beta heterozygote knockout mice as a model of findings in postmortem schizophrenia brain or as a model of behaviors mimicking lithium action: negative results. Behav Pharmacol (2008) 1.12
Treatment of bipolar depression. N Engl J Med (2007) 1.11
Lithium's effect in forced-swim test is blood level dependent but not dependent on weight loss. Behav Pharmacol (2007) 1.09
Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients. Am J Psychiatry (2000) 1.07
Dopamine D4 receptor and serotonin transporter promoter in the determination of neonatal temperament. Mol Psychiatry (1998) 1.05
Psychotropic drugs affect Ser9-phosphorylated GSK-3 beta protein levels in rodent frontal cortex. Int J Neuropsychopharmacol (2005) 1.05
Knockout mice in understanding the mechanism of action of lithium. Biochem Soc Trans (2009) 1.02
Reduced GSK-3beta mRNA levels in postmortem dorsolateral prefrontal cortex of schizophrenic patients. J Neural Transm (Vienna) (2004) 1.01
Are omega-3 fatty acids antidepressants or just mood-improving agents? The effect depends upon diagnosis, supplement preparation, and severity of depression. Mol Psychiatry (2012) 1.00
Low GSK-3 activity in frontal cortex of schizophrenic patients. Schizophr Res (2001) 1.00
Omega 3 fatty acid treatment in autism. J Child Adolesc Psychopharmacol (2009) 1.00
Polymorphisms in the dopamine D4 receptor gene (DRD4) contribute to individual differences in human sexual behavior: desire, arousal and sexual function. Mol Psychiatry (2006) 1.00
The lessons of platelet monoamine oxidase. Psychol Med (1984) 0.99
Valnoctamide as a valproate substitute with low teratogenic potential in mania: a double-blind, controlled, add-on clinical trial. Bipolar Disord (2010) 0.98
Ritual female genital surgery among Ethiopian Jews. Arch Sex Behav (1997) 0.98
Additional evidence for an association between the dopamine D4 receptor (D4DR) exon III repeat polymorphism and the human personality trait of Novelty Seeking. Mol Psychiatry (1998) 0.96
Inositol treatment in psychiatry. Psychopharmacol Bull (1995) 0.96
Personality and polymorphisms of genes involved in aminergic neurotransmission. Eur J Pharmacol (2000) 0.96
Animal models of the mechanisms of action of repetitive transcranial magnetic stimulation (RTMS): comparisons with electroconvulsive shock (ECS). Depress Anxiety (2000) 0.96
TPQ in euthymic manic-depressive patients. J Psychiatr Res (1997) 0.95
Double-blind, controlled trial of inositol treatment of depression. Am J Psychiatry (1995) 0.95
Transcranial magnetic stimulation induces alterations in brain monoamines. J Neural Transm (Vienna) (1997) 0.95
No association between global leukocyte DNA methylation and homocysteine levels in schizophrenia patients. Schizophr Res (2008) 0.95
Combination of lithium carbonate and haloperidol in schizo-affective disorder: a controlled study. Arch Gen Psychiatry (1979) 0.95
The effect of transcranial magnetic stimulation of rat brain on behavioral models of depression. Brain Res (1995) 0.94
Slow magnetic stimulation of prefrontal cortex in depression and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (1997) 0.94
Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. Biol Psychiatry (2006) 0.94
Lithium research: state of the art. Biol Psychiatry (1990) 0.94
Homocysteine levels in newly admitted schizophrenic patients. J Psychiatr Res (2004) 0.93
Dopamine D4 receptor (D4DR) and serotonin transporter promoter (5-HTTLPR) polymorphisms in the determination of temperament in 2-month-old infants. Mol Psychiatry (1999) 0.93
The high affinity inositol transport system--implications for the pathophysiology and treatment of bipolar disorder. Bipolar Disord (2000) 0.92
The effects of inositol treatment in animal models of psychiatric disorders. J Affect Disord (2001) 0.92
The effect of lithium on noradrenaline-induced cyclic AMP accumulation in rat brain: inhibition after chronic treatment and absence of supersensitivity. J Pharmacol Exp Ther (1980) 0.91
Reduced frontal cortex inositol levels in postmortem brain of suicide victims and patients with bipolar disorder. Am J Psychiatry (1997) 0.91
No association between the serotonin transporter gene regulatory region polymorphism and the Tridimensional Personality Questionnaire (TPQ) temperament of harm avoidance. Mol Psychiatry (1997) 0.91
Lithium dosage and inositol levels. Br J Psychiatry (1994) 0.90
Epi-inositol regulates expression of the yeast INO1 gene encoding inositol-1-P synthase. Mol Psychiatry (2002) 0.89
Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone. J Clin Psychiatry (2001) 0.89
Lithium inhibitable enzymes in postmortem brain of bipolar patients. J Psychiatr Res (2003) 0.89
Effects of lithium in vitro and ex vivo on components of the adenylate cyclase system in membranes from the cerebral cortex of the rat. Neuropharmacology (1987) 0.89
Hyperfunctional G proteins in mononuclear leukocytes of patients with mania. Biol Psychiatry (1991) 0.89
Biogenic amine-related enzymes and personality variations in normals. Psychol Med (1977) 0.88
Preliminary evaluation of oral anticonvulsant treatment in the quinpirole model of bipolar disorder. J Neural Transm (Vienna) (2002) 0.88
The possible involvement of glycogen synthase kinase-3 (GSK-3) in diabetes, cancer and central nervous system diseases. Curr Pharm Des (2011) 0.87
Family-based and case-control study of catechol-O-methyltransferase in schizophrenia among Palestinian Arabs. Am J Med Genet B Neuropsychiatr Genet (2003) 0.87
5-HT2C (HTR2C) serotonin receptor gene polymorphism associated with the human personality trait of reward dependence: interaction with dopamine D4 receptor (D4DR) and dopamine D3 receptor (D3DR) polymorphisms. Am J Med Genet (1997) 0.87
Effects of lithium on lipopolysaccharide-induced inflammation in rat primary glia cells. Innate Immun (2011) 0.86
The effect of lithium on expression of genes for inositol biosynthetic enzymes in mouse hippocampus; a comparison with the yeast model. Brain Res Mol Brain Res (2003) 0.86
Lithium preferentially inhibits adenylyl cyclase V and VII isoforms. Int J Neuropsychopharmacol (2008) 0.86
Right prefrontal TMS versus sham treatment of mania: a controlled study. Bipolar Disord (2003) 0.86
Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder. Am J Psychiatry (1995) 0.86
Behavioral evidence for the existence of two pools of cellular inositol. Eur Neuropsychopharmacol (1994) 0.86
Ziskind-Somerfeld Research Award 1993. Biochemical, behavioral, and clinical studies of the role of inositol in lithium treatment and depression. Biol Psychiatry (1993) 0.86
Inositol treatment of obsessive-compulsive disorder. Am J Psychiatry (1996) 0.85
Bayesian approach to bipolar guidelines. World J Biol Psychiatry (2010) 0.85
High homocysteine serum levels in young male schizophrenia and bipolar patients and in an animal model. Prog Neuropsychopharmacol Biol Psychiatry (2005) 0.85
Lithium nephrotoxicity. Int J Bipolar Disord (2015) 0.85
Disappearance of female genital mutilation from the Bedouin population of Southern Israel. J Sex Med (2009) 0.85
Lack of lithium-like behavioral and molecular effects in IMPA2 knockout mice. Neuropsychopharmacology (2006) 0.85
The antidepressant activity of inositol in the forced swim test involves 5-HT(2) receptors. Behav Brain Res (2001) 0.85
SMIT1 haploinsufficiency causes brain inositol deficiency without affecting lithium-sensitive behavior. Mol Genet Metab (2006) 0.85
Inositol reduces depressive-like behaviors in two different animal models of depression. Psychopharmacology (Berl) (1999) 0.83
Inositol treatment raises CSF inositol levels. Brain Res (1993) 0.83
Transmission disequilibrium and haplotype analyses of the G72/G30 locus: suggestive linkage to schizophrenia in Palestinian Arabs living in the North of Israel. Am J Med Genet B Neuropsychiatr Genet (2006) 0.83
Human platelet monoamine oxidase changes during the menstrual cycle. Arch Gen Psychiatry (1974) 0.83
Saga of an adventure gene: novelty seeking, substance abuse and the dopamine D4 receptor (D4DR) exon III repeat polymorphism. Mol Psychiatry (1997) 0.83
Interstrain correlation between behavioural effects of lithium and effects on cortical cyclic AMP. Pharmacol Biochem Behav (1986) 0.83
Possible involvement of post-dopamine D2 receptor signalling components in the pathophysiology of schizophrenia. Int J Neuropsychopharmacol (2007) 0.82
A possible cardiovascular effect of lithium. Am J Psychiatry (1979) 0.82
Copy number variation of the SELENBP1 gene in schizophrenia. Behav Brain Funct (2010) 0.82
Phenytoin as an antimanic anticonvulsant: a controlled study. Am J Psychiatry (2000) 0.82
Intravenous diazepam in the treatment of neuroleptic-induced acute dystonia and akathisia. Am J Psychiatry (1978) 0.82
A comparison of the ability of myo-inositol and epi-inositol to attenuate lithium-pilocarpine seizures in rats. Biol Psychiatry (1996) 0.82
The effect of propranolol treatment in shizophrenia on CSF amine metabolites and prolactin. Psychopharmacology (Berl) (1979) 0.82
Inositol levels are decreased in postmortem brain of schizophrenic patients. Biol Psychiatry (1998) 0.82
Subsensitivity of human beta-adrenergic adenylate cyclase after salbutamol treatment of depression. Psychopharmacology (Berl) (1981) 0.81
Mitochondrial DNA HV lineage increases the susceptibility to schizophrenia among Israeli Arabs. Schizophr Res (2007) 0.81
Evidence for an association between the dopamine D3 receptor gene DRD3 and schizophrenia. Hum Hered (1997) 0.81
Lurasidone and bipolar disorder. Am J Psychiatry (2014) 0.81
Chronic treatment of human astrocytoma cells with lithium, carbamazepine or valproic acid decreases inositol uptake at high inositol concentrations but increases it at low inositol concentrations. Brain Res (2000) 0.81
Trehalose induced antidepressant-like effects and autophagy enhancement in mice. Psychopharmacology (Berl) (2013) 0.81